Gastrointestinal and hepatic involvement in paediatric systemic lupus erythematosus

Sandra Trapani1, Chiara Rubino2, Gabriele Simonini3

  • 1Meyer Children's University Hospital, Department of Health Sciences, University of Florence, Italy. sandra.trapani@unifi.it.

Insights

Gastrointestinal issues are common in pediatric lupus erythematosus (pSLE), often presenting with non-specific symptoms. Early diagnosis and treatment with immunosuppressants are key for managing these challenging manifestations.

Area of Science:

  • Pediatric Rheumatology
  • Gastroenterology
  • Autoimmune Diseases

Background:

  • Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting multiple organ systems.
  • Gastrointestinal (GI) involvement is well-documented in adult SLE but less understood in pediatric-onset SLE (pSLE).

Purpose of the Study:

  • To provide a comprehensive review of GI involvement in pSLE.
  • To summarize current knowledge on prevalence, pathogenesis, clinical features, diagnosis, and management of GI issues in pSLE.

Main Methods:

  • A narrative review of literature published from 2000 to August 2020.
  • Searches conducted on PubMed and EMBASE databases.

Main Results:

  • Lupus enteritis is the most common GI manifestation in pSLE, followed by pseudo-obstruction, protein-losing enteropathy, hepatic disease, and pancreatitis.
  • Common symptoms include abdominal pain, anorexia, nausea, and vomiting, often alongside other SLE signs.
  • Complications like perforation and infarction are life-threatening; early diagnosis and treatment improve outcomes.

Conclusions:

  • GI involvement is a frequent and challenging aspect of pSLE.
  • Most pSLE GI manifestations respond to glucocorticoids and immunosuppressants.
  • Further research is needed to clarify prevalence, prognosis, and optimal treatment strategies.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
87
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
95
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
101
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
74
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
118
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
547